Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 6, 03 August 2023
Open
Access | Article
Clinical efficacy of sodium dependent glucose transporters 2 inhibitor in the treatment of heart failure
* Author to whom correspondence should be addressed.
Abstract
When it comes to diseases, heart failure is always an important issue for people around the whole world. Patients may suffer a lot when they have heart failure. Every year, there are a lot of people who dead because of having Heart Failure in and out of America. Nowadays, there are mainly two types of heart failures, HFrEF (heart failure reduced ejection fraction) and HFpEF (heart failure preserved ejection fraction). Research show that SGLT2 including Dapagliflozin, sotagliflozin, empagliflozin, and other types of inhibitors are effective when used to treat with heart failure patients regardless of whether they have had diseases like diabetes before. With the support of researches mentioned in the following passage, this idea will be reliable and we believe that with such kind of good news that the SGLT2 inhibitor are actually contributing to the process of dealing with HF, people who have been suffer from HF will one day be able to cured.
Keywords
SGLT2 inhibitors, HFrEF, HFpEF
References
1. Saisho, Y. (2020). SGLT2 inhibitors: the star in the treatment of type 2 diabetes?. Diseases, 8(2), 14.
2. Verma S, et al (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol
3. Sattar N, et al (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia
4. J.J.V. McMurray, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med, 381 (2019)
5. T.A. Zelniker, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet, 393 (2019), P31-39
6. V. Perkovic, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy N Engl J Med, 380 (2019), P2295-2306
7. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials; Dimitrios Patoulias, et al, 2022.
8. John D. et al. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management; 2017
9. Sean P Murphy, et al;Heart Failure With Reduced Ejection Fraction: A Review; 2020.
10. McMurray, et al. "Dapagliflozin in patients with heart failure and reduced ejection fraction." New England Journal of Medicine 381.21 (2019): 1995-2008.
11. Stefan D. et al., Empagliflozin in Heart Failure with a Preserved Ejection Fraction; 2021
12. Kurmani S, et al. Acute Heart Failure: Definition, Classification and Epidemiology. Current Heart Failure Reports. 2017;14(5):385-392.
13. Deepak L., et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure; 2021.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230180
- Copyright
- 03 August 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited